Table 1. Characteristics of the 105 patients.
| Patient characteristics | na | % |
|---|---|---|
| Age, years (median, range) | 71 (65-81) | |
| Sex: | ||
| Male | 61 | 58.1 |
| Female | 44 | 41.9 |
| ECOG performance status: | ||
| 0 | 54 | 51.4 |
| 1 | 51 | 48.6 |
| Stage: | ||
| IIIB | 11 | 10.5 |
| IV | 94 | 89.5 |
| EGFR mutation: | ||
| Exon 18 | 1 | 0.9 |
| Exon 19 | 39 | 37.1 |
| Exon 20 | 3 | 2.9 |
| Exon 21 | 16 | 15.2 |
| Wild-type | 40 | 38.1 |
| Unknown | 6 | 5.8 |
| ALK translocation: | ||
| Positive | 0 | 0 |
| Negative | 88 | 83.8 |
| Unknown | 17 | 16.2 |
| Metastatic sites: | ||
| Supraclavicular lymph nodes | 18 | 17.1 |
| Bone | 46 | 43.8 |
| Lung | 32 | 30.5 |
| Liver | 10 | 9.5 |
| Brain | 13 | 12.4 |
| Effusion: | ||
| Pleural effusion | 35 | 33.3 |
| Pericardial effusion | 10 | 9.5 |
| Adrenal gland | 2 | 1.9 |
| Other | 4 | 3.7 |
| Metastases: | ||
| 1-3 | 96 | 91.4 |
| >3 | 9 | 8.6 |
| Smoking history: | ||
| Never | 61 | 58.1 |
| Current/former | 44 | 41.9 |
| Coexisting morbidities: | ||
| None | 63 | 60.0 |
| Hypertension | 26 | 24.8 |
| Diabetes | 7 | 6.7 |
| Other | 9 | 8.6 |
| Weight loss >5kg/0.5 year: | ||
| No | 101 | 96.2 |
| Yes | 4 | 3.8 |
a Unless otherwise specified.
Abbreviations: ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.